SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon. “We are excited to share add ...

Core Insights - iBio, Inc. has announced promising pharmacokinetics data for IBIO-600, a long-acting anti-myostatin antibody, suggesting a potential human half-life of up to 130 days, which could position it as a best-in-class treatment for muscle preservation and weight loss [1][4][5] - The company is on track to submit a regulatory application for IBIO-600 in Q1 2026, highlighting its commitment to innovation in obesity treatment [1][5] Group 1: IBIO-600 Development - The pharmacokinetics study involved non-human primates (NHPs) and indicated a half-life of 40 to 52 days in NHPs, with human estimates ranging from 57 to 130 days [4] - The study demonstrated a dose-dependent increase in lean mass and a reduction in fat mass, with the low-dose group showing a 3.1% increase in lean mass and the high-dose group a 5.1% increase after 8 weeks [3] - The potential for a dosing schedule of once every 3 to 6 months could significantly reduce the treatment burden for patients [4][5] Group 2: Activin E Antibody - iBio has also disclosed preclinical data for a first-in-class Activin E antibody, which effectively blocks Activin E signaling and shows promise as a novel obesity treatment [5] - In an exploratory study with obese mice, the Activin E antibody as a monotherapy resulted in a 4% fat-selective weight loss and an 18% reduction in total body fat compared to placebo [5] - When combined with semaglutide, the Activin E antibody enhanced total weight loss by an additional 9%, leading to an overall weight reduction of 34% and a 72% reduction in body fat [5]